YG
Therapeutic Areas
Galmed Pharmaceuticals Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Aramchol Meglumine | NASH and Fibrosis | Phase 3 |
| Amilo-5MER | Inflammatory Diseases | Preclinical |
Leadership Team at Galmed Pharmaceuticals
AB
Allen Baharaff
Chief Executive Officer & President
DC
Doron Cohen
Chief Financial Officer
LH
Liat Hayardeny - Brueck, Ph.D.
Chief Scientific Officer
GN
Guy Nehemya, Adv.
Chief Operating Officer
YS
Yohai Stenzler, CPA
Chief Accounting Officer
TG
Tali Gorfine, M.D.
Executive Clinical Development Consultant
JP
John Posner
Clinical Pharmacology Specialist
SE
Shaul E. Kadosh
Biostatistical & Clinical Research Consultant
JK
Joseph Kaspi, Ph.D.
Senior CMC Director (Consultant)
DM
Dalia Medini, Ph.D.
Analytical Advisor (Consultant)